e-Therapeutics unveils results of its strategic review under new chief executive
e-Therapeutics plans to control its costs by reducing the number of self-funded discovery programmes from six to two
Company
e-Therapeutics PLC
LON:ETX
e-Therapeutics PLC is integrating computational power and biology to accelerate the discovery of life-transforming RNAi medicines. The company has developed and validated a powerful computational approach to drug discovery, leveraging our industry-leading expertise in network biology to fully capture and interrogate human disease complexity. e-Therapeutics' multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support.
153 stories · page 2 of 2
Archive
Proactive news round-up: Lombard Risk Management, Acal, Symphony Environmental Technologies …
A glance at some of the stories on the Proactive newswire today
Drug developer e-Therapeutics streamlines its operation
“We are now focusing on our core strengths around our unique drug discovery platform and the discovery of novel preclinical drugs," said chairman Iain Ross.
Archive
Day ahead: Retailers at opposite ends of shopping spectrum in focus
Luxury group Burberry PLC will deliver a pre-close season trading update, while Primark discount clothing chain owner Associated British Foods PLC delivers its first-half results
Archive
Primark to keep the ball rolling nicely at Associated British Foods
Week ahead; Associated British Foods , Sky , Unilever Burberry, Reckitt Benckiser...
Triad Group shares surge after saying it expects full year profit growth
Some of the largest share price rises and falls in London at 4pm: Triad Group, Hardide, Weatherly
First day for new e-Therapeutics boss
Dr Raymond Barlow arrives from Amgen, where he held a senior role
FTSE 100 finishes lower as Fed's easy money set to end
The index of blue-chip shares succumbed to selling pressure
Archive
Proactive news round-up: EG Solutions, Avation, Gulfsands Petroleum ...
A glance at some of the stories on the Proactive newswire today.
Metal Tiger strongly extends yesterday's leap; Laura Ashley drops
The main risers and fallers around 2.45pm included Metal Tiger, CloudTag, Laura Ashley ...
Investments and investor services
FTSE shares ease with lower Wall St and ex-dividend stocks
FTSE 100 shares closed lower, dragged down by weaker US stocks and a flurry of ex-dividend stocks in London
Archive
Proactive news round-up: Orogen Gold, Braveheart Investment, Concepta ...
A glance at some of the stories on the Proactive newswire today
e-Therapeutics appoints Amgen heavy-hitter as new CEO
Dr Raymond Barlow brings with him a “broad experience of drug discovery, development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector”, ETX said.
Archive
Proactive news round-up: Range Resources, LGO Energy, Corero Network Security ...
A glance at some of the stories on the Proactive newswire today
e-Therapeutics director buys shares with fees
The group said he subscribed for 36,917 new shares at 7.45p each worth around £2,750.
Risers & Fallers: Crossrider, EVR Holdings, Scotgold...
Major share price risers and fallers in London at 3.45pm
e-Therapeutics refocused and well-funded
The company underwent something of a transition in the first six months of the year, reorganising its board and shifting its focus
Change of focus leads to departure of development director at e-Therapeutics
Pharma veteran Steve Self is moving on following the company's decision to focus on its discovery platform
E-Therapeutics' chief executive steps down
Iain Ross, the current chairman, will take on an executive role while the company looks for a new chief executive.
Proactive news highlights: Deltex Medical, e-Therapeutics, Motif Bio, Sula Iron and more...
Deltex Medical Group has hailed the “superb results”, Tissue Regenix beefs up its board and MySQUAR updates on the success of its first game.
Proactive news highlights: Anglo Pacific, e-Therapeutics, Eurasia mining, Forbidden Technologies and more
Graphene NanoChem receives an order for its oilfield recovery additive, e-Therapeutics tells investors that it remains well funded and Forbidden Technology partners with an energy drink.
e-Therapeutics well-funded and focused on commercialisation
The firm is well funded, with a last reported cash balance of £24.8mln.
Proactive news highlights: Versarien, Ten Alps, Sound Energy, SyndicateRoom and more...
Versarien pairs with winter Olympian, Ten Alps wins a Bafta and Antonio Banderas to star in SyndicateRoom's film.
e-Therapeutics in £2.3mln search engine technology deal
Searchbolt, the business being bought, was spun-off from ETX when the latter was listed on stock market in 2007
e-Therapeutics plc homing in on commercialisation
e-Therapeutics is now targeting partners to accelerate the development of its drug discovery engine and commercialise compounds.
Junior oilers in favour as small cap shares outshine Footsie
Junior oil stocks were in favour on Tuesday and small cap indices were ahead of Footsie.
Xeros Technology Group PLC leads AIM 100 higher
It was a mixed start for London's junior market but revolutionary laundry system developer Xeros has scrubbed up very well
e-Therapeutics plc looking for partners as it focuses on discovery platform
e-Therapeutics plc is targeting partners to accelerate the development of its drug discovery engine, it told investors.
Archive
Proactive news summary: Windar Photonics, 88 Energy, Metal Tiger, Egdon Resources and more.
Everything appears to being going to plan for 88 Energy in Alaska...
Risers & Fallers: Action Hotels, CAP-XX, First Property Group, Iofina, Nature Group, Premier African
A tremendous boost for Premier African Minerals, the operator and 49% stakeholder in the RHA tungsten project, which has had a financing offer from local financial institution.
e-Therapeutics to take more time to assess mixed trial data
The side effects and tolerance profile of ETS6103 were found to be more benign than amitriptyline.
Investments and investor services
Proactive news highlights: APC Technology, Patagonia Gold, Cloudtag, Corero Network and more
African Potash, e-Therapeutics and sound Energy also reported on Wednesday
e-Therapeutics hires life sciences veteran as chairman
Professor Malcolm Young is stepping down as chairman but will remain in his role as chief executive.
Investments and investor services
Proactive news highlights: Goldplat, Seeing Machines, Acal, Arian Silver, Utilitywise, Mirada...
Fastjet, Ortac Resourves and Genel Energy also had news out...
Archive
Proactive (non-mining) news summary: Active Energy, Aggregated Micro, Globo, Learning Technologies .
The end of quarter is approaching so companies were rushing out end-June trading updates, leading to a very heavy news day.
E-Therapeutics eyes full control of discovery platform tech
E-Therapeutics ended its latest half year with cash of more than £30mln.
Investments and investor services
Tuesday's agenda: Wolseley to highlight strength of US economy
Wolseley and Boohoo.com lead the companies reporting on Tuesday...
Archive
Week Ahead: Sainsbury's to update on the trolley wars
Sainsbury is likely to report continued hard times for the grocers.
Four Exciting Companies to present in London on Thursday 24th September
The management from eg Solutions, e-Therapeutics, Motif Bio & Amphion Innovations will be updating investors on current developments and future prospects .
Four Exciting Companies to present in London on Thursday 17th September
The management from e-Therapeutics (LON:ETX), Ergomed (LON:ERGO), Tissue Regenix (LON:TRX) and TekCapital (LON:TEK) will be updating investors on current developments and future prospects.
Investments and investor services
Oil majors drag London lower despite upbeat Greek news
European indices climb after Eurogroup approves Greek bailout
Builders and building materials
FTSE 100 ends flat as housebuilders dominate news
UK stocks managed to pare most of its losses on the day...
Cancer drug firms to cash in on $9bn immunotherapy market
Trials have shown that immunotherapy may revolutionise cancer treatment
e-Therapeutics bullish on discovery platform
"With the progress we are making both in the clinical programmes and in discovery, we expect another exciting year,"